You kindly agreed to act as an investigator in an important Phase lll diabetes trial some two years ago.  You will not have to administer any injections, only monitor your patients. 

The Phase ll results are outstanding

Data from the Phase ll diabetes clinical trials in the Netherlands are set out below:

In the previous trials of four months duration, all drug therapy was withdrawn from the participating patients. They were given 4 injections spaced one week apart which resulted in the maintenance of  mean HbA1c level of  6.6 in the treated group, while in the placebo group the mean HbA1c levels increased to 9.8.  

Green line = Diabetic patients receiving placebo only
Blue line = Diabetic patients who received a low dose of the new treatment
Orange line = Diabetic patients who received intermediate dose of the new treatment
Red line = Diabetic patients who who received higher dose of the new treatment

Figure 1. HbA1c levels in male diabetes mellitus type 2 patients after withdrawal of anti-diabetic drugs. Average data  are shown; bars indicate the standard error of the mean.  Placebo (green) vs high dose (red) p= 0.0003, overall p= 0.0044.

templa38

4 months --------->


Figure 2. Graph represents 4 months. Fasting capillary glucose levels in male diabetes mellitus type 2 patients after withdrawal of anti-diabetic drugs. Average data are shown; bars indicate the standard error of the mean. Placebo vs high dose p=0.005, overall p=0.024  

templa37

4 months --------->


Figure 3. Photo shows optical density results demonstrating the strength efficacy of the site binding reactions of the new drug 

      


 If you wish to continue to help your patients in this clinical trial in diabetes, please click HERE

We thank you for your support.